Medication info
Newstatin T.S. Tablet 80/5/10 Milligrams

Newstatin T.S. Tablet 80/5/10 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Samjin Pharmaceutical Co., Ltd.
Appearance
Oval-shaped bilayer tablet consisting of a white layer and a light blue layer
Packaging
30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 201802237 · Approved 2018.05.30 · Insurance code 647804700

Summary

Main use
Treatment of dyslipidemia and hypertension, inhibition of the progression of atherosclerosis, and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time every day (e.g., in the morning). This medicine should be administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking the telmisartan/amlodipine combination together with rosuvastatin as a single agent, they may switch to this medicine (a combination tablet containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose of each individual ingredient (amlodipine or telmisartan) be adjusted. However, if blood pressure is not controlled with the individual ingredients as described below, switching directly to the telmisartan/amlodipine combination may be considered. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. In patients with severe renal impairment, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Older patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, start treatment at a low dose and increase the dose gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased up to a maximum of 20 mg per day. 2. Older patients: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of telmisartan/amlodipine 80/10mg and rosuvastatin 20mg, the active ingredients of this medicine, the Cmax of rosuvastatin increased by approximately 2.1-fold and its AUC increased by approximately 1.2-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, the potential risks associated with the increase in rosuvastatin Cmax should be assessed, and patients should be monitored closely.

Ingredients

Manufacturer
Samjin Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia and hypertension, inhibition of the progression of atherosclerosis, and prevention of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used only in patients with essential hypertension whose blood pressure is not adequately controlled with either telmisartan or amlodipine alone and in cases where rosuvastatin needs to be administered simultaneously. The telmisartan/amlodipine combination effectively controls and stabilizes blood pressure. Rosuvastatin calcium improves lipid disorders such as hypercholesterolemia and is used as an adjunct to diet when not controlled by diet and exercise. This medication also helps slow the progression of atherosclerosis and reduce the risk of stroke, myocardial infarction, and revascularization in patients at risk for cardiovascular disease by controlling both blood pressure and cholesterol simultaneously, thus effectively improving cardiovascular health.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time every day (e.g., in the morning). This medicine should be administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking the telmisartan/amlodipine combination together with rosuvastatin as a single agent, they may switch to this medicine (a combination tablet containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose of each individual ingredient (amlodipine or telmisartan) be adjusted. However, if blood pressure is not controlled with the individual ingredients as described below, switching directly to the telmisartan/amlodipine combination may be considered. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. In patients with severe renal impairment, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Older patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, start treatment at a low dose and increase the dose gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer, according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased up to a maximum of 20 mg per day. 2. Older patients: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. In a drug interaction study of telmisartan/amlodipine 80/10mg and rosuvastatin 20mg, the active ingredients of this medicine, the Cmax of rosuvastatin increased by approximately 2.1-fold and its AUC increased by approximately 1.2-fold in the presence of telmisartan/amlodipine. Therefore, when administering this medicine, the potential risks associated with the increase in rosuvastatin Cmax should be assessed, and patients should be monitored closely.

Precautions

This medication should not be used during pregnancy as it may cause serious harm to the fetus and newborn. If pregnancy is confirmed, discontinuation should occur immediately. Do not take this medication if you are allergic to any of its ingredients or have certain genetic diseases, severe liver or kidney diseases. Particularly, patients with a history of angioedema, severe aortic stenosis, myopathy, and severe renal impairment should not take this medication. Patients with hypertension, decreased liver function, elderly patients, and those with hyperkalemia should use this medication cautiously and monitor liver function tests and muscle-related tests periodically. If symptoms such as muscle pain or weakness appear, consult a doctor immediately and discontinue if necessary. This medication may interact with various other drugs, so inform your healthcare provider of any other medications you are taking. Women of childbearing potential should use appropriate contraception and it is recommended not to use this medication while breastfeeding. Safety and efficacy have not been well established for children under 18 years of age; therefore, it is not recommended. For elderly patients, especially those over 75 years old, it is advisable to start with a lower dose and gradually increase. In cases of overdose, symptoms such as low blood pressure, dizziness, and cardiac abnormalities may occur, so visit a medical institution immediately. Keep this medication out of the reach of children and do not transfer it to another container for safety.

Side effects

  • Peripheral edema
  • dyspepsia
  • frequent bowel movements
  • diabetes
  • dizziness
  • dry vesicular sound
  • urticaria
  • unstable angina
  • onychomycosis
  • lumbar spinal stenosis
Show 164 more
  • ear discharge
  • vertigo
  • chronic gastritis
  • various gastrointestinal disorders
  • hiatal hernia
  • dysuria
  • rhinitis
  • discomfort in the oropharynx
  • lung disease
  • nonspecific intestinal disease
  • benign gastrointestinal neoplasm
  • hemorrhoids
  • skeletal pain
  • osteoporosis
  • sensory impairment
  • movement disorders
  • atherosclerosis
  • frequent urination
  • tinnitus
  • hearing loss
  • halitosis
  • fatty liver
  • upper respiratory infection
  • low back pain
  • sinusitis
  • diarrhea
  • pharyngitis
  • influenza-like symptoms
  • dyspepsia
  • myalgia
  • urinary tract infection
  • abdominal pain
  • headache
  • dizziness
  • pain
  • fatigue
  • cough
  • hypertension
  • chest pain
  • nausea
  • erectile dysfunction
  • erectile dysfunction
  • increased sweating
  • flushing
  • allergy
  • fever
  • leg pain
  • fatigue
  • palpitations
  • dependency edema
  • angina
  • rapid pulse
  • leg edema
  • abnormal ECG
  • insomnia
  • drowsiness
  • migraine
  • dizziness
  • sensory abnormalities
  • involuntary muscle contractions
  • sensory impairment
  • flatulence
  • constipation
  • gastritis
  • vomiting
  • dry mouth
  • hemorrhoids
  • gastroenteritis
  • enteritis
  • gastroesophageal reflux
  • toothache
  • nonspecific gastrointestinal disease
  • gout
  • hypercholesterolemia
  • diabetes
  • arthritis
  • joint pain
  • leg numbness
  • anxiety
  • depression
  • irritability
  • infection
  • fungal infection
  • abscess
  • otitis media
  • asthma
  • bronchitis
  • rhinitis
  • respiratory distress
  • nosebleed
  • dermatitis
  • rash
  • eczema
  • pruritus
  • angioedema
  • erythema multiforme
  • vasculitis
  • peripheral neuropathy
  • tremors
  • anorexia
  • dysphagia
  • pancreatitis
  • gingival hyperplasia
  • weakness
  • burning sensation
  • fatigue
  • rigidity
  • weight gain
  • weight loss
  • sexual dysfunction
  • insomnia
  • irritability
  • abnormal dreams
  • depersonalization
  • eosinophilia
  • leukopenia
  • purpura
  • thrombocytopenia
  • angioedema
  • Stevens-Johnson syndrome
  • jaundice
  • hepatitis
  • lupus-like syndrome
  • muscle rupture
  • immune-mediated necrotizing myopathy
  • hematuria
  • edema
  • depression
  • sleep disorders
  • interstitial lung disease
  • sexual dysfunction
  • gynecomastia
  • fatal and non-fatal liver failure
  • memory impairment
  • forgetfulness
  • amnesia
  • memory disorders
  • confusion
  • hypotension
  • tachycardia
  • bradycardia
  • acute renal failure
  • elevated serum potassium
  • thrombocytopenia
  • elevated serum creatinine
  • myalgia
  • increased CK
  • elevated ALT
  • elevated AST
  • weakness
  • joint pain
  • fatigue
  • numbness
  • sensory abnormalities
  • chest discomfort
  • nausea
  • abdominal pain
  • diarrhea
  • anorexia
  • abdominal distension
  • syncope
  • generalized pain
  • muscle cramps
  • gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in an opaque container that does not allow light to enter. Additionally, it is important to store the medication at room temperature, between 1 degree and 30 degrees Celsius, to maintain its effectiveness.

Appearance and packaging

Appearance

Oval-shaped bilayer tablet consisting of a white layer and a light blue layer

Package unit

30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.